5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients

S.Loibl; J.Pfisterer; P.Wimberger; C.Kurzeder; A.Du Bois; J.Sehouli; A.Belau; N.Burchardi; I.Vergote; U.Wagner

首页> 外文期刊>European Journal of Cancer Supplements >5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients

【24h】

5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients

机译：5005 ORAL腹膜内注入三功能双特异性抗体catumaxomab（抗EpCAM×抗CD3）的随机，多中心，2剂量水平，开放标签IIa期研究，以选择难治性铂类上皮性卵巢癌患者的更好剂量水平

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共1页
作者
S.Loibl; J.Pfisterer; P.Wimberger; C.Kurzeder; A.Du Bois; J.Sehouli; A.Belau; N.Burchardi; I.Vergote; U.Wagner;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. [J] . Baumann K, Pfisterer J, Wimberger P, Gynecologic Oncology: An International Journal . 2011,第1期

机译：三功能双特异性抗体Catumaxomab的腹膜内治疗对铂耐药的上皮性卵巢癌患者：AGO研究小组的IIa期研究。
2. First surgical experience of intraperitoneal treatment with the trifunctional antibody catumaxomab (anti-EpCam x anti-CD3) for epithelial ovarian cancer. [J] . Papanikolaou G, Fotopoulou C, Braicu I, Anticancer Research: International Journal of Cancer Research and Treatment . 2011,第8期

机译：三功能抗体catumaxomab（抗EpCam x抗CD3）腹膜内治疗上皮性卵巢癌的首次外科手术经验。
3. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial [J] . Raymund Buhmann, Stanglmaier Michael, Hess Juergen, Journal of Translational Medicine . 2013,第1期

机译：同种异体干细胞移植后复发或难治性B细胞淋巴瘤中使用三功能双特异性抗CD3 x抗CD20抗体FBTA05（Bi20）和供体淋巴细胞输注（DLI）进行免疫治疗：研究者驱动的开放标签研究方案，非随机，不受控制，剂量递增的I / II试验阶段
4. Immunotherapy with FBTA05 (Bi20) a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven open-label non-randomized uncontrolled dose-escalating Phase I/II-trial [O] . Raymund Buhmann, Stanglmaier Michael, Hess Juergen, 2013

机译：同种异体干细胞移植后复发或难治性B细胞淋巴瘤中使用三功能双特异性抗CD3 x抗CD20抗体FBTA05（Bi20）和供体淋巴细胞输注（DLI）进行免疫治疗：研究者驱动的开放标签研究方案非随机不受控制剂量递增的I / II试验阶段
5. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial [O] . 2013

机译：同种异体干细胞移植后复发或难治性B细胞淋巴瘤中使用三功能双特异性抗CD3 x抗CD20抗体FBTA05（Bi20）和供体淋巴细胞输注（DLI）进行免疫治疗：研究者驱动的开放标签研究方案，非随机，不受控制，剂量递增的I / II试验阶段

5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients

著录项

相似文献

相关主题

期刊订阅